



**THERMOGENESIS CORP. TO PRESENT AT  
DEUTSCHE BANK SECURITIES HEALTH CARE CONFERENCE ON  
WEDNESDAY, MAY 3, 2006**

RANCHO CORDOVA, Calif., April 27, 2006 - **ThermoGenesis Corp. (NASDAQ: KOOL)** announced today that Mr. Philip H. Coelho, the Company's Chairman and Chief Executive Officer, and Mr. Matthew Plavan, Chief Financial Officer, will participate in the Deutsche Bank Securities 31st Annual Health Care Conference to be held May 2 and 3, 2006 at the Sheraton Boston Hotel in Boston, Massachusetts. Mr. Coelho is scheduled to present an overview of the Company's business activities and product pipeline at 10:30 AM Eastern time on Wednesday, May 3, 2006.

To listen to the audio web cast of the presentation during or after the event, please visit: [http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=KOOL&item\\_id=1230100](http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=KOOL&item_id=1230100)

The presentation will also be accessible on the Deutsche Bank Securities website for 90 days after the conference.

**About ThermoGenesis Corp.**

ThermoGenesis Corp. is a leader in developing and manufacturing automated blood processing systems and disposables that enable the manufacture, preservation and delivery of cell and tissue therapy products.

- **The BioArchive® System**, an automated cryogenic device, is used by cord blood stem cell banks in 29 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- **The AutoXpress™ System**, is a newly developed semi-automated device and companion sterile closed blood processing disposable, to harvest stem cells from cord blood.
- **The CryoSeal® FS System**, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. Enrollment in a 150-patient U.S. pivotal clinical trial has been completed and a PMA is being reviewed by the FDA.
- **The Thrombin Processing Device™ (TPD™)** is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of plasma in less than 30 minutes. The TPD market launch is underway in Europe.

This press release, including statements regarding financial information for future periods, contain forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking

statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2006, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2006. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements.

For More Information, Contact:

THERMOGENESIS CORP.

Or Fern Lazar of Lazar Partners (212) 867-1762

or visit the web site at [www.thermogenesis.com](http://www.thermogenesis.com)